• Profile
Close

Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B

Journal of Hepatology Aug 19, 2020

Papatheodoridis GV, Dalekos GN, Idilman R, et al. - Looking at patients in the multicenter European PAGE-B cohort, researchers examined if patients receiving tenofovir disoproxil fumarate (TDF) vs entecavir (ETV) differ in hepatocellular carcinoma (HCC) incidence or any other patient outcomes. They assessed 1,935 Caucasians with chronic hepatitis B (CHB), with or without compensated cirrhosis, who underwent treatment with either ETV (n = 772) or TDF (n = 1,163) monotherapy. Up to 12 years, similar rates of hepatocellular carcinoma, biochemical/virological response, HBsAg loss and mortality were seen among Caucasians with CHB treated with ETV vs TDF. However, relative to ETV treated patients, those receiving TDF more frequently had elastographic reversion of cirrhosis at year 5.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay